Search Results - "MELO, Junia"

Natural course and biology of CML by Chereda, Bradley, Melo, Junia V.

“…Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the haemopoietic stem cell (HSC) compartment. This disease is characterised by a…”
Get full text

Chronic myeloid leukaemia as a model of disease evolution in human cancer by Melo, Junia V, Barnes, David J

“…Chronic myeloid leukaemia (CML) can be considered as a paradigm for neoplasias that evolve through a multi-step process. CML is also one of the best examples…”
Get full text

Cancer stem cell definitions and terminology: the devil is in the details by Valent, Peter, Bonnet, Dominique, De Maria, Ruggero, Lapidot, Tsvee, Copland, Mhairi, Melo, Junia V., Chomienne, Christine, Ishikawa, Fumihiko, Schuringa, Jan Jacob, Stassi, Giorgio, Huntly, Brian, Herrmann, Harald, Soulier, Jean, Roesch, Alexander, Schuurhuis, Gerrit Jan, Wöhrer, Stefan, Arock, Michel, Zuber, Johannes, Cerny-Reiterer, Sabine, Johnsen, Hans E., Andreeff, Michael, Eaves, Connie

“…This article outlines some of the issues surrounding the terminology used for cancer stem cells (CSCs) and how CSCs are defined, with an aim to develop a…”
Get full text

Prof. Daniel Catovsky Buenos Aires 19 September 1937—London 2 December 2022 by Foà, Robin, Melo, Junia V., Rai, Kanti K.

Get full text

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study by Ross, David M., Branford, Susan, Seymour, John F., Schwarer, Anthony P., Arthur, Christopher, Yeung, David T., Dang, Phuong, Goyne, Jarrad M., Slader, Cassandra, Filshie, Robin J., Mills, Anthony K., Melo, Junia V., White, Deborah L., Grigg, Andrew P., Hughes, Timothy P.

“…Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn. We conducted a prospective clinical trial of…”
Get full text

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? by Branford, Susan, Melo, Junia V., Hughes, Timothy P.

“…Preclinical studies of BCR-ABL mutation sensitivity to nilotinib or dasatinib suggested that the majority would be sensitive. Correspondingly, the initial…”
Get full text

A kinase-independent role for CDK8 in BCR-ABL1+ leukemia by Menzl, Ingeborg, Zhang, Tinghu, Berger-Becvar, Angelika, Grausenburger, Reinhard, Heller, Gerwin, Prchal-Murphy, Michaela, Edlinger, Leo, Knab, Vanessa M., Uras, Iris Z., Grundschober, Eva, Bauer, Karin, Roth, Mareike, Skucha, Anna, Liu, Yao, Hatcher, John M., Liang, Yanke, Kwiatkowski, Nicholas P., Fux, Daniela, Hoelbl-Kovacic, Andrea, Kubicek, Stefan, Melo, Junia V., Valent, Peter, Weichhart, Thomas, Grebien, Florian, Zuber, Johannes, Gray, Nathanael S., Sexl, Veronika

“…Cyclin-dependent kinases (CDKs) are frequently deregulated in cancer and represent promising drug targets. We provide evidence that CDK8 has a key role in…”
Get full text

Resistance to imatinib mesylate in chronic myeloid leukaemia by Melo, Junia V, Chuah, Charles

“…Abstract Despite the remarkable results achieved with imatinib for the treatment of chronic myeloid leukaemia, the emergence of resistance to this tyrosine…”
Get full text

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition by Mitchell, Rebecca, Hopcroft, Lisa E M, Baquero, Pablo, Allan, Elaine K, Hewit, Kay, James, Daniel, Hamilton, Graham, Mukhopadhyay, Arunima, O'Prey, Jim, Hair, Alan, Melo, Junia V, Chan, Edmond, Ryan, Kevin M, Maguer-Satta, Véronique, Druker, Brian J, Clark, Richard E, Mitra, Subir, Herzyk, Pawel, Nicolini, Franck E, Salomoni, Paolo, Shanks, Emma, Calabretta, Bruno, Holyoake, Tessa L, Helgason, G Vignir

“…Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically significantly improved the life expectancy of…”
Get full text

Another Year to Celebrate Advances in Clinical Hematology by Mohty, Mohamad, Melo, Junia V.

Get full text

Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia by Blatt, Katharina, Menzl, Ingeborg, Eisenwort, Gregor, Cerny-Reiterer, Sabine, Herrmann, Harald, Herndlhofer, Susanne, Stefanzl, Gabriele, Sadovnik, Irina, Berger, Daniela, Keller, Alexandra, Hauswirth, Alexander, Hoermann, Gregor, Willmann, Michael, Rülicke, Thomas, Sill, Heinz, Sperr, Wolfgang R., Mannhalter, Christine, Melo, Junia V., Jäger, Ulrich, Sexl, Veronika, Valent, Peter

“…Leukemic stem cells (LSCs) are an emerging target of curative anti-leukemia therapy. In acute lymphoblastic leukemia (ALL), LSCs frequently express CD34 and…”
Get full text

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition by Mitchell, Rebecca, Hopcroft, Lisa E M, Baquero, Pablo, Allan, Elaine K, Hewit, Kay, James, Daniel, Hamilton, Graham, Mukhopadhyay, Arunima, O’Prey, Jim, Hair, Alan, Melo, Junia V, Chan, Edmond, Ryan, Kevin M, Maguer-Satta, Véronique, Druker, Brian J, Clark, Richard E, Mitra, Subir, Herzyk, Pawel, Nicolini, Franck E, Salomoni, Paolo, Shanks, Emma, Calabretta, Bruno, Holyoake, Tessa L, Helgason, G Vignir

Get full text

One Year into the COVID-19 Pandemic by Mohty, Mohamad, Melo, Junia V.

Get full text

Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells by Kominsky, Douglas J, Klawitter, Jelena, Brown, Jaimi L, Boros, Laszlo G, Melo, Junia V, Eckhardt, S Gail, Serkova, Natalie J

“…The development of imatinib resistance has become a significant therapeutic problem in which the etiology seems to be multifactorial and poorly understood. As…”
Get full text

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models by Mahon, François-Xavier, Belloc, Francis, Lagarde, Valérie, Chollet, Claudine, Moreau-Gaudry, François, Reiffers, Josy, Goldman, John M., Melo, Junia V.

“…Inappropriate expression of the multidrug resistance(MDR1)gene encoding the P-glycoprotein (Pgp) has been frequently implicated in resistance to different…”
Get full text

Mechanisms of resistance to BCR-ABL kinase inhibitors by Diamond, Joana M., Melo, Junia V.

“…Since the introduction of imatinib mesylate (IM) for the treatment of chronic myeloid leukemia (CML), impressive clinical responses have been observed in the…”
Get full text

The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia by Mohty, Mohamad, Yong, Agnes S.M., Szydlo, Richard M., Apperley, Jane F., Melo, Junia V.

“…Because the polycomb group gene BMI1 regulates the proliferation of both normal and leukemic stem cells, we examined whether BMI1 expression was associated…”
Get full text

Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications by HIWASE, Devendra K, SAUNDERS, Verity, HUGHES, Timothy P, WHITE, Deborah L, HEWETT, Duncan, FREDE, Amity, ZRIM, Stephanie, DANG, Phuong, EADIE, Laura, BIK TO, L, MELO, Junia, KUMAR, Sharad

“…Purpose: The organic cation transporter OCT-1 mediates active transport of imatinib. We recently showed that low OCT-1 activity is a major contributor to…”
Get full text

Inactivation of HOXA Genes by Hypermethylation in Myeloid and Lymphoid Malignancy is Frequent and Associated with Poor Prognosis by STRATHDEE, Gordon, HOLYOAKE, Tessa L, JORGENSEN, Heather G, SOUTAR, Richard, BROWN, Robert, SIM, Alyson, PARKER, Anton, OSCIER, David G, MELO, Junia V, MEYER, Stefan, EDEN, Tim, DICKINSON, Anne M, MOUNTFORD, Joanne C

“…Purpose: The HOX genes comprise a large family of homeodomain-containing transcription factors, present in four separate clusters, which are key regulators of…”
Get full text

The molecular biology of chronic myeloid leukemia by Deininger, Michael W.N., Goldman, John M., Melo, Junia V.

Get full text